Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Accounts Payables (2021 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Accounts Payables for 5 consecutive years, with $168450.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 142.81% year-over-year to $168450.0, compared with a TTM value of $168450.0 through Oct 2025, up 142.81%, and an annual FY2024 reading of $60749.0, up 17.18% over the prior year.
  • Accounts Payables was $168450.0 for Q4 2025 at VitaNova Life Sciences, up from $67431.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $168450.0 in Q4 2025 and bottomed at $28563.0 in Q2 2021.
  • Average Accounts Payables over 5 years is $57977.6, with a median of $50672.5 recorded in 2022.
  • The sharpest move saw Accounts Payables dropped 4.94% in 2023, then soared 142.81% in 2025.
  • Year by year, Accounts Payables stood at $36691.0 in 2021, then soared by 45.38% to $53343.0 in 2022, then decreased by 4.94% to $50707.0 in 2023, then surged by 36.82% to $69375.0 in 2024, then skyrocketed by 142.81% to $168450.0 in 2025.
  • Business Quant data shows Accounts Payables for YJGJ at $168450.0 in Q4 2025, $67431.0 in Q3 2025, and $72181.0 in Q1 2025.